InvestorsHub Logo

Markipeach

12/18/19 6:48 PM

#235739 RE: raistthemage #235737

Exactly. Its Sales and Marketing 101!!!

relocatedmetsfan

12/18/19 10:19 PM

#235795 RE: raistthemage #235737

raist - "victory in the 1st amendment case"


I believe that your understanding of the results of Amarin's 1st Amendment win over the FDA is incorrect. If I'm recalling correctly, this win allows for Amarin to communicate factual details about Vascepa and results from studies, but only to medical professionals.

For instance, Amarin can send out an email containing the following information...



(c/o @greenday_bio on Twitter


The FDA label only says people with Trigs at and above 150 mg/dL. However, since Amarin is able to show that the 5-point MACE results from REDUCE-IT were consistent in the subgroup of people with Trigs below 150 mg/dL as they were with above 150, they can relay this information to doctors. They would not be able to include this on any direct-to-customer advertisements.